At Mawdsleys Specialist Pharma, we offer a broad range of seamless services for Pharma companies:
A Named Patient Programme (NPP) – often called an Early Access Programme – provides a safe, legal and ethical route for physicians and patients to access medications that have not yet been licensed or made commercially available in their home country. Reasons why patients may not have a licensed treatment option available include a medicine being new and part of a clinical trial, or a previously licensed medicine being discontinued.
We have a successful track record of partnering with small and mid-size companies in launching such programmes, and are able to advise on their design, regulatory compliance and implementation. We can provide a bespoke, turnkey solution to provide patients with access to the medicines they need, while you’re able to see levels of demand and control the information passed to and from the healthcare provider. We will oversee access in accordance with your particular commercial and clinical parameters.
The Pharma Partner
Using our expertise and global experience, a Named Patient Programme can bring a range of benefits for your pharma company:
We’re well-versed in managing the whole process of getting your product licensed in new territories on your behalf, with wide-ranging experience in submissions to regulatory bodies, navigating the process and ensuring a smooth route to commercialisation.
With a focus on high added value products, we’re always keen to find breakthrough medical innovations for the healthcare community through in-licensing and long-term partnerships with small and mid-sized speciality pharmaceutical companies.
If you’re looking for a forward-thinking proactive partner with the knowledge, experience and capability to help your pharma company, we’d love to talk to you. So please get in touch.
"*" indicates required fields